Trattamento della iperfosforemia del paziente uremico: I nuovi chelanti

Blacher J. , Guerin A.P. , Pannier B. , Marchais S. , London G.M. Arterial calcifications, arterial stiffness and cardiovascular risk in end stage renal disease. Hypertension 2001; 38: 938–42.

Block G.A. , Hulbert-Shearon T.E. , Levin N.W. , Port F.K. Association of serum phosphorus and calciumxphopshate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–12.

Block G.A. , Klassen P.S. , Lazarus J.M. Mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208–18.

Jono S. , McKee M.D. , Murry C.E. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: 7–10.

Chertow G.M. , Burke S.K. , Lazarus J.M. Polyallylamine hydrochloride (Renagel). A non calcemic phosphate binder for the treatment of hyperphosphataemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66–77.

De Santo N.G. , Frangiosa A. , Marino A. , Iacono G. , Savica V. , Cirillo M. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006; 19(suppl 9): S108–14.

Slatopolsky E. , Burke S.K. , Dillon M.A. Renagel a nonabsorbed calcium and aluminium free phosphate binder, lowers serun phosphorus and parathyroid hormone. Kidney Int 1999; 55: 298–307.

Chertow G.M. , Burke S.K. , Dillon M.A. , Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphorus product and the lipide profile of hemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907–14.

Chertow G.M. , Burke S.K. , Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 242–52.

Qunibi W.Y. , Hoottkins R.E. , McDowell L.L. Treatment of hyperphosphatemia in hemodyalisis patients: The Calcium Acetate Renagel evaluation (CARE Study). Kidney Int 2004; 65: 1914–26.

Block G.A. , Spiegel D.M. , Ehrlich J. , Metha R. , Lindbergh J. , Dreisbach A. , Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68: 1815–24.

Suki W. , Zabaneh R. , Cangiano J. A prospective randomized trial assessing the impact on outcomes of sevelamer in dialysis patients - the DCOR Trial. ERAEDTA 2006; Abstract SP392.

Block G.A. , Raggi P. , Kooienga L. , Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71(5): 438–44.

Raggi P. , James G. , Bueke S.K. Decrease in thoracic vertebral attenuation with calcium based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764–72.

Ferreira A. , Frazao J. , Faugere M. Effects of sevelamer and calcium carbonate on bone mineralisation and turnover in chronic maintenance haemodialysis patients. ERAEDTA 2006; Abstracts MO016 iv293.

Ferramosca E. , Burke S. , Chasan-Taber S. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820–5.

Yamada K. , Fujimoto S. , Tokura T. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance he-

DeSmet R. , Thermote F. , Lameire N. Sevelamer hydrochloride (Renagel) adsorbs the uremic compounds indoxyl sulfate, indole and p-cresol. J Am Soc Nephrol 2004; 15: 505A. Abstract.

Freemont A.J. Lanthanum Carbonate. Drugs Today 2006; 42(12): 759–70.

Damment S.J. , Totten W. The pharmacology of a new phosphate binder, lanthanum carbonate. Nephrol Dial Transplant 2003; 18: 683–9.

Hutchinson A.J. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 2004; 19(suppl 1): S19–24.

Behets G.J. , Gritters M. , Dams G. , De Broe M.E. , D'Haese P.C. Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 2005; 27: 475–84.

Behets G.J. , Verberckmoes S.C. , D'Haese P.C. , De Broe M.E. Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens 2004; 13: 403–9.

Pennick M. , Dennis K. , Damment S. Absolute bioavail-ability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006; 64: 428–37.

Hutchinson A.J. , Speake M. , Al-Baaj F. Reducing high phopshate levels in patients with chronic renal failure undergoing dialysis: a 4-week dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004; 19: 1902–6.

Al-Baaj F. , Speake M. , Hutchinson A.J. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continous ambulatorial peritoneal dialysis in a short term, placebo-controlled study. Nephrol Dial Transplant 2005; 20: 775–82.

Hutchinson A.J. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: c8–c19.

Finn W.F. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 191–202.

Finn W.F. , Joy M.S. A long term open label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005; 21: 657–64.

Hutchinson A.J. , Maes B. , Vanwalleghem J. Long term efficacy and tolerability of lanthanum carbonate. Results from a 3-year of study. Nephron Clin Pract 2006; 102: c61–c71.

Behets G.J. , Verberckmoes S.C. , Oste L. Localisation of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005; 67: 1830–6.

Behets G.J. , Gritters M. , Dams G. , De Broe M.E. , Haese P.C. Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 2005; 27: 475–84.

Damment S.J. , Shen V. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralisation in uremic rats. Clin Nephrol 2005; 63: 127–37.

D'Haese P.C. , Spasovsky G.B. , Sikole A. A Multicenter study on the effects of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 85(suppl): S73–8.

Malluche H.H. , Faugere M.C. , Wang G. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. J AM Soc Nephrol 2004; Abstract (F-PO944), 15: 270A

Spasovski G.B. , Sikole A. , Gelev S. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after two years of follow-up. Nephrol Dial Transplant 2006; 21: 2217–24.

Yang Z. , Schryvers D. , Roels F. , D'Haese PC , De Broe M.E. Demonstration of lanthanum in liver cells by energy -dispersive X ray spectroscopy, electron energy loss spectroscopy and high resolution transmission electron microscopy. J Microsc 2006; 223: 133–9.

Ben-Dov I.Z. , Pappo O. , Sklair-Levy M. , Galitzer H. Ilan Yaron, Naveh-Many T Lanthanum carbonate decreases PTH gene expression with no Hepatoxicity in Uraemic rats. Nephrol Dial Transplant 2007; 22: 362–8.

Lacour B. , Lucas A. , Auchere D. , Ruellan N. , De Serre Patey N.M. , Drue T.B. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062–9.

Slatopolsky E. , Liapis H. , Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809–13.

Jones C. , Webster I. , Damment S.J.P. Lack of CNS adverse events with lanthanum carbonate-preclinical and clinical data. 19° ERAEDTA 2004; Lisbon, Portugal. Poster.